Public Health Agency

Strengthening Canada's bail system to help keep communities safe

Retrieved on: 
Tuesday, May 16, 2023
Weapon, Survivor, Minister, Minister of Intergovernmental Affairs, Infrastructure and Communities, FPT, Justice Select Committee, Partnership, Criminal law, Justice, Violence, Crime, The Honourable, Criminal code, Law enforcement, Health promotion, Criminal Code (Canada), Mental health, Data collection, Rights, IPV, Intimate partner violence, Person, Government, Violent crime, Parliament, Firearm, Minister of Mental Health and Addictions, Section 7 of the Canadian Charter of Rights and Freedoms, Investment, Public security, Child, Randeep Sarai, Community, PHAC, Public Health Agency of Canada, Government of Canada, Bill, Federation, The Criminal Code, Addiction, Trauma, Public Health Agency, Safety, Legislation, Nursing, Drug, Health

There are specific challenges facing our bail system posed by repeat violent offending, firearms, and other dangerous weapons that need to be addressed.

Key Points: 
  • There are specific challenges facing our bail system posed by repeat violent offending, firearms, and other dangerous weapons that need to be addressed.
  • Bill C-48 proposes to make targeted changes to the Criminal Code's bail regime to ensure our communities stay safe.
  • It is making significant investments to prevent crime and keep communities safe, and address the causes of crime as well.
  • Canadians deserve to be safe and feel safe in their communities and to have confidence that the criminal justice system will protect them and work as intended.

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
D&O, Marketing, Tubing (recreation), Public Health Agency of Canada, Clinical trial, Woman, Infertility, Fertility, Diagnosis, Research, Public Health Agency, Health Canada, SXSW, D, Cryptocurrency, Birth control

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • General and administrative expenses decreased by $132,218 to $1,315,137 for the three months ended March 31, 2023, from $1,447,355 for the three months ended March 31, 2022.
  • Sales and marketing expenses increased by $176,033 to $244,896 for the three months ended March 31, 2023, from $68,863 for the three months ended March 31, 2022.
  • Cost of sales decreased by $17,555 to $105,120 for the three months ended March 31, 2023, from $122,675 for the three months ended March 31, 2022.
  • Gross margin percentage was 64.2% for the three months ended March 31, 2023, as compared to 61.8% for the three months ended March 31, 2022.

Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada

Retrieved on: 
Wednesday, May 3, 2023
Colposcopy, Bleeding, Public Health Agency of Canada, C More Entertainment, Woman, Pain, Cervical cancer, Diagnosis, Public Health Agency, Health Canada, Medical imaging

ATLANTA, May 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Health Canada, the Public Health Agency of Canada, has granted product approval of FemCerv®, the first endocervical tissue sampler (curette) designed to collect and contain a comprehensive sample to maximize quality and quantity. FemCerv captures a tissue sample in a relatively pain-free manner and has the potential to be an improvement over the existing standard of care to diagnose the presence of cancerous cells in a woman’s cervix.

Key Points: 
  • FemCerv captures a tissue sample in a relatively pain-free manner and has the potential to be an improvement over the existing standard of care to diagnose the presence of cancerous cells in a woman’s cervix.
  • “We are delighted to gain another product approval in Canada, with FemCerv now available to women throughout all of North America as a more advanced alternative for tissue sampling to detect cervical cancer,” stated Kathy Lee-Sepsick, Femasys’ founder, president and, chief executive officer.
  • The tools available to collect this tissue are limited and can cause pain, bleeding and extreme discomfort, as well as result in an inadequate or contaminated sample.
  • Further, should sample contamination occur, this would require subsequent tests and office visits to obtain additional samples.

Government of Canada invests $8.5 million to the Canadian Red Cross to support the mental health of people across the country

Retrieved on: 
Tuesday, May 2, 2023
Knowledge, Canadian Red Cross, University, Social, Parent, Public Health Agency of Canada, COVID-19, Mental health, Renison University College, Indigenous peoples, Human, Government, Minister of Mental Health and Addictions, Investment, A Friendly Call, International Red Cross and Red Crescent Movement, Red, Indigenous self-government in Canada, Parliament, Public Health Agency, Caregiver, Nursing, Pharmaceutical industry, Health, Addiction

Today, Élisabeth Brière, Parliamentary Secretary to the Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, announced $8.5 million in funding to expand the Canadian Red Cross' Friendly Calls program.

Key Points: 
  • Today, Élisabeth Brière, Parliamentary Secretary to the Honourable Carolyn Bennett, Minister of Mental Health and Addictions and Associate Minister of Health, announced $8.5 million in funding to expand the Canadian Red Cross' Friendly Calls program.
  • At a regularly scheduled time, Red Cross personnel call the people with whom they are paired for a social chat, connecting them, if needed, with resources available in their community.
  • "Supporting the mental health of all Canadians, including those already facing disproportionate challenges to their mental health, is a priority for our government.
  • This announcement is part of a $100 million investment provided in Budget 2021, to support projects that promote mental health and prevent mental illness in populations disproportionately impacted by the COVID-19 pandemic.

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

Retrieved on: 
Tuesday, April 18, 2023
Health Canada, Birth, Public Health Agency of Canada, Clinical trial, Woman, Infertility, IVF, Patent, ICSI, IDE, FDA, Public Health Agency, First Ever, Birth control

ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the Health Canada, the Public Health Agency of Canada, has granted product approval of FemaSeed®, the first-ever infertility solution designed to deliver sperm directly to where contraception occurs. FemaSeed is Femasys’ localized artificial insemination option that is designed to be less invasive and more affordable than assisted reproduction, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • FemaSeed is Femasys’ localized artificial insemination option that is designed to be less invasive and more affordable than assisted reproduction, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
  • “We are thrilled to gain approval of FemaSeed in Canada, now being able to offer a safe, novel and affordable option for treating infertility,” stated Kathy Lee-Sepsick, Femasys’ founder, president, chief executive officer.
  • “Our advanced approach delivers sperm directly to the area where conception occurs in the fallopian tube.
  • Prior to FemaSeed, Femasys’ first-of-its-kind in-office ultrasound diagnostic product FemVue®, which is also approved in Canada, can be used to assess that the fallopian tube is patent.

High steady state of COVID-19 case levels are a concern, according to CoVaRR-Net experts

Retrieved on: 
Thursday, April 13, 2023
Pillar, DNA, University, Vaccination, SARS-CoV-2, Genomics, Public Health Agency of Canada, COVID-19, Absenteeism, Immunity, COVID, CAMEO, Ventilation, Computable analysis, Risk, Simon Fraser University, Public Health Agency, Distinguishing, Pharmaceutical industry, Vaccine

“The waves have changed from big peaks and low troughs to smaller waves (or wavelets) centering around an overall higher COVID level.

Key Points: 
  • “The waves have changed from big peaks and low troughs to smaller waves (or wavelets) centering around an overall higher COVID level.
  • “Like glacial melt raising sea levels, the higher transmissibility of XBB.1.5 and waning immunity are raising the sea level of COVID-19 cases.
  • Discover CAMEO’s Duotang , a continually updated web-based notebook that contains a wide range of genomic epidemiology and mathematical modelling analyses.
  • The data for Duotang is compiled from the Canadian VirusSeq Data Portal and DNA Stack’s Viral AI .

LUCARA ANNUAL GENERAL AND SPECIAL MEETING TO BE HELD MAY 12, 2023

Retrieved on: 
Monday, April 10, 2023
Diamond, Euroclear, Euclidean distance, Shareholder, Internet, Bank statement, Eastern Time Zone, Telephone, Public Health Agency of Canada, COVID-19, Annual, Lucara Diamond, Suite, Blake, Cassels & Graydon, CDS, Corporation, SEDAR, Special, Coronavirus, Computershare, ONT, Public Health Agency, Remuneration, Audit, Property management, Security (finance), Auction, Bay Street, Proxy, Meeting

The record date for the Annual General and Special Meeting is March 15, 2023.

Key Points: 
  • The record date for the Annual General and Special Meeting is March 15, 2023.
  • The Notice of Meeting, the accompanying Management Proxy Circular and related meeting materials are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at https://lucaradiamond.com .
  • The Corporation encourages you to vote your shares by proxy in advance of the Meeting, via mail, telephone or on the internet.
  • Shareholders who hold Euroclear Registered Securities are not registered holders of voting securities for the purposes of voting at the Meeting.

STATEMENT - Domestic dog tests positive for avian influenza in Canada

Retrieved on: 
Tuesday, April 4, 2023
Fox, Human, National Centre for Foreign Animal Disease, HPAI, Detection dog, Foreign animal disease, Public Health Agency of Canada, Mammal, Canadian Food Inspection Agency, Porpoise, Kathrin Glock, Respiratory system, World Health Organization, CFIA, WOAH, Government, Raccoon, Risk, Dog, Dolphin, Government of Canada, Health, Public Health Agency, Bird, Safety, Cat, Bottled water, Vaccine

The domestic dog was found to have been infected with avian influenza after chewing on a wild goose, and died after developing clinical signs.

Key Points: 
  • The domestic dog was found to have been infected with avian influenza after chewing on a wild goose, and died after developing clinical signs.
  • Based on the current evidence in Canada, the risk to the general public remains low and current scientific evidence suggests that the risk of a human contracting avian influenza from a domestic pet is minor.
  • Furthermore, no domestically acquired human cases of avian influenza have been reported in Canada.
  • We are tracking avian influenza activity in Canada and around the world, with domestic and international partners, including the World Health Organization.

Vision care is health care: Canada's vision health stakeholders collectively stress the need to support vision care in federal budget

Retrieved on: 
Wednesday, March 29, 2023
Private, Overalls, U.S. federal government response to the COVID-19 pandemic, Hospital Insurance and Diagnostic Services Act, Paratriathlon, Visual impairment, Quality of life, Canadian Association of Optometrists, Research, Federal, Government, Parliament, Federation, Person-centered therapy, Long COVID, Eye, Computer science and engineering, Government of Canada, Diagnosis, Health, Public Health Agency, American Ophthalmological Society, Health insurance, Pharmaceutical industry, Management, Optometry

More than 1.2 million Canadians live with vision loss today, and over 8 million Canadians live with one of the four major eye diseases.

Key Points: 
  • More than 1.2 million Canadians live with vision loss today, and over 8 million Canadians live with one of the four major eye diseases.
  • In 2019, the total cost of vision loss in Canada was $32.9 billion, resulting in 9.5 billion in direct health system costs.
  • Given the importance of vision health and its substantial impact on overall health spending, the national vision health stakeholders look forward to having further discussions with the Government of Canada to see where vision care can be supported under this new budget.
  • With the goal of working collaboratively with provinces and territories, the strategies developed will create efficient, cost-effective access to eye health and vision care to all Canadians.

New survey data reveals that between April and August 2022, 98% of Canadian adults had antibodies to SARS-CoV-2

Retrieved on: 
Monday, March 27, 2023
Infection, COVID-19 Immunity Task Force, Vaccination, SARS-CoV-2, Statistics, Public Health Agency of Canada, COVID-19, Policy, Antibody, DBS, Incidence, Immunity, Data, CITF, PHAC, Statistics Canada, Health, Public Health Agency, Vaccine, Health insurance

This survey provides a nationally representative measure of the population with antibodies to SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • This survey provides a nationally representative measure of the population with antibodies to SARS-CoV-2, the virus that causes COVID-19.
  • Between April and August 2022, 54% of Canadian adults – or about 16.4 million Canadians – had antibodies indicating a past infection to SARS-CoV-2.
  • Between April and August 2022, nearly all Canadian adults (98.1%) had antibodies against SARS-CoV-2, acquired through vaccination, a previous infection or both.
  • The DBS tests were used to estimate the number of Canadian adults who have infection-acquired and/or vaccine-induced antibodies to SARS-CoV-2.